Substance use histories in patients seeking treatment for controlled-release oxycodone dependence

被引:44
|
作者
Potter, JS
Hennessy, G
Borrow, JA
Greenfield, SF
Weiss, RD
机构
[1] McLean Hosp, Belmont, MA 02478 USA
[2] Harvard Univ, Sch Med, Belmont, MA 02478 USA
关键词
prescription opiate abuse; oxycodone; pain patients;
D O I
10.1016/j.drugalcdep.2004.05.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The characteristics of patients currently abusing control led-release (CR) oxycodone admitted for inpatient detoxification were ascertained from medical record review of 48 inpatients with CR oxycodone dependence. Patients were categorized according to the manner in which they initially received the drug: illicitly or by prescription for legitimate medical use. Fifteen of the 48 patients (31%) initially obtained a CR oxycodone prescription legitimately for a medical condition. While none of these 15 patients had a history of prior opioid misuse, they were more likely than illicit CR oxycodone users to report prior detoxifications (P < 0.03) as well as a lower mean age of first alcohol use (legitimate = 11.7 versus illicit = 14.7, P < 0.05) and first illicit drug use (legitimate = 12.8 versus illicit = 15.8, P < 0.05). These findings suggest that a history of substance abuse is common among patients abusing CR oxycodone, including individuals for whom CR oxycodone was initially legitimately prescribed for pain. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:213 / 215
页数:3
相关论文
共 50 条
  • [41] Treatment of cancer pain with Q12H oral controlled-release oxycodone
    Allende-Perez, S
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 1505 - 1508
  • [42] Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial
    Markenson, JA
    Croft, J
    Zhang, PG
    Richards, P
    CLINICAL JOURNAL OF PAIN, 2005, 21 (06): : 524 - 535
  • [43] Trends and uptake of new formulations of controlled-release oxycodone in Canada
    Gomes, Tara
    Jain, Sonia
    Paterson, J. Michael
    Sketris, Ingrid
    Caetano, Patricia
    Henry, David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (05) : 520 - 525
  • [44] Safety and efficacy of controlled-release oxycodone: A systematic literature review
    Rischitelli, DG
    Karbowicz, SH
    PHARMACOTHERAPY, 2002, 22 (07): : 898 - 904
  • [45] PHARMACOKINETIC MODEL FOR A NEW ORAL CONTROLLED-RELEASE FORMULATION OF OXYCODONE
    MANDEMA, JW
    KAIKO, RF
    OSHLACK, B
    REDER, RF
    STANSKI, DR
    ANESTHESIOLOGY, 1994, 81 (3A) : A383 - A383
  • [46] The use of a high dose of controlled-release oxycodone in a switch from oral morphine: a case report
    Leppert, Wojciech
    Werner, Sebastian
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2011, 15 (05): : 333 - 336
  • [47] A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients
    Nosek, Krzysztof
    Leppert, Wojciech
    Nosek, Hanna
    Wordliczek, Jerzy
    Onichimowski, Dariusz
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2409 - 2419
  • [48] Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: A placebo-controlled, randomized study
    Cloutier, C.
    Taliano, J.
    O'Mahony, W.
    Csanadi, M.
    Cohen, G.
    Sutton, I.
    Sinclair, D.
    Awde, M.
    Henein, S.
    Robinson, L.
    Eisenhoffer, J.
    Piraino, P. S.
    Harsanyi, Z.
    Michalko, K. J.
    PAIN RESEARCH & MANAGEMENT, 2013, 18 (02): : 75 - 82
  • [49] Clinical Equivalence of Controlled-Release Oxycodone 20 mg and Controlled-Release Tramadol 200 mg after Surgery for Breast Cancer
    Kampe, Sandra
    Wolter, Karsten
    Warm, Mathias
    Dagtekin, Oguzhan
    Shaheen, Sasan
    Landwehr, Susanne
    PHARMACOLOGY, 2009, 84 (05) : 276 - 281
  • [50] Controlled-release oxycodone (OxyContin®) provides analgesia in painful diabetic neuropathy
    Gimbel, J
    Mollen, M
    Richards, P
    Zhang, PG
    Dhanda, R
    Mihalik, MC
    McCroskery, E
    Portenoy, R
    DIABETES, 2001, 50 : A175 - A175